3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Kidney Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Interventions
Carboplatin
3
fludarabine
2
Radiotherapy, Intensity-Modulated
2
Pemetrexed
2
Cyclophosphamide
2
Cisplatin
2
Cerebral Decortication
2
pembrolizumab
1
fludarabine phosphate
1
Platinum
1
Fluorodeoxyglucose F18
1
Blood Component Removal
1
Bevacizumab
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
Blood Component Removal
×
30 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled